Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications

 Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications

Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications

Shots:

  • Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the net profit of the therapies
  • Junshi to get WW exclusive rights for the production and commercialization of these drugs and will be responsible for clinical trial applications. The companies will jointly facilitate the pre-clinical research work of the therapies
  • WJ1024/WJ1075 is an XPO1 inhibitor, WJ05129 is an Aurora-A inhibitor, APL1898 is an EGFR-exon20 inhibitor while the last drug is an effective fourth-generation EGFR inhibitor

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Wigen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post